Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
The closing price of ATAI Life Sciences N.V (NASDAQ: ATAI) was $2.05 for the day, up 11.41% from the previous closing price of $1.84. In other words, the price has increased by $11.41 from its previous closing price. On the day, 7.2 million shares were traded. ATAI stock price reached its highest trading level at $2.13 during the session, while it also had its lowest trading level at $1.66.
Ratios:
Our analysis of ATAI’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.07 and its Current Ratio is at 4.07. In the meantime, Its Debt-to-Equity ratio is 0.19 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on November 18, 2024, Reiterated its Buy rating but revised its target price to $10 from $15 previously.
On April 03, 2024, Maxim Group Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $6.
On November 01, 2022, Loop Capital started tracking the stock assigning a Buy rating and target price of $18.Loop Capital initiated its Buy rating on November 01, 2022, with a $18 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 21 ’25 when Kirpekar Sahil sold 48,563 shares for $1.35 per share. The transaction valued at 65,560 led to the insider holds 115,636 shares of the business.
Craig Kevin James sold 11,563 shares of ATAI for $15,610 on Mar 21 ’25. The Chief Medical Officer now owns 8,437 shares after completing the transaction at $1.35 per share. On Mar 21 ’25, another insider, Rao Srinivas, who serves as the insider of the company, sold 75,418 shares for $1.35 each. As a result, the insider received 101,814 and left with 212,942 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ATAI now has a Market Capitalization of 410692896 and an Enterprise Value of 290040896. For the stock, the TTM Price-to-Sale (P/S) ratio is 1244.52 while its Price-to-Book (P/B) ratio in mrq is 2.69. Its current Enterprise Value per Revenue stands at 155.685 whereas that against EBITDA is -3.036.
Stock Price History:
The Beta on a monthly basis for ATAI is 1.33, which has changed by 0.2275449 over the last 52 weeks, in comparison to a change of 0.11936104 over the same period for the S&P500. Over the past 52 weeks, ATAI has reached a high of $2.57, while it has fallen to a 52-week low of $1.03. The 50-Day Moving Average of the stock is 41.82%, while the 200-Day Moving Average is calculated to be 42.34%.
Shares Statistics:
ATAI traded an average of 1.82M shares per day over the past three months and 2261580 shares per day over the past ten days. A total of 199.78M shares are outstanding, with a floating share count of 134.40M. Insiders hold about 32.91% of the company’s shares, while institutions hold 9.82% stake in the company. Shares short for ATAI as of 1745971200 were 12193805 with a Short Ratio of 6.69, compared to 1743379200 on 11682579. Therefore, it implies a Short% of Shares Outstanding of 12193805 and a Short% of Float of 7.9799999999999995.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The performance of ATAI Life Sciences N.V (ATAI) in the stock market is under the watchful eye of 2.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.11, with high estimates of -$0.09 and low estimates of -$0.13.
Analysts are recommending an EPS of between -$0.42 and -$0.58 for the fiscal current year, implying an average EPS of -$0.5. EPS for the following year is -$0.71, with 3.0 analysts recommending between -$0.39 and -$0.92.
